CYBN:CC News and Press, CYBIN INC. From 06/02/22

Image Cybin Inc. (NEO: CYBN) (NYSE:CYBN), a biopharmaceutical company focused on advancing “psychedelics into therapeutics”, just announced a monumental milestone toward advancing CYB003 into clinical development. CYB003 is a deuterated psilocybin analog desi...

Last week, the Oregon Health Authority adopted new administrative rules to govern testing and training programs for psilocybin as well as psilocybin products. These rules, as well as others that have not yet been finalized, will go into effect in January 2023, when Oregon’s therapeu...

In today’s world, we spend most of our day in front of a screen, be it a phone, laptop or computer. While what we’re doing may be productive, overusing technology may have a negative effect on mental health. This is why undergoing a digital and/or social detox to help disconn...

Study shows that COVID-19 pandemic has affected mental health of 59% of U.S. population, intensifying already-serious issue CYBN-sponsored feasibility study indicates ketamine-induced changes in brain’s functional connectivity persisted for several days after receiving the substa...

Cybin (NYSE American: CYBN) (NEO: CYBN) , a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced the submission of an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FD...

-- CYB003 is the first psilocybin analog to be evaluated in Phase 1/2a development for the treatment of major depressive disorder -- Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing ...

These past few years, an increasing number of studies on psychedelics have been conducted, with researchers finding that these substances may be used as alternative treatments for mental health conditions such as depression and anxiety. The latest data from World Health Organization shows ...

Recent study indicates psychedelic compounds show significant promise in treating a range of mental-health disorders Participants given psilocybin therapy reported a rapid, sustained improvement in their depression Cybin’s CYB003 has demonstrated less variability, faster onset,...

The Commonwealth Scientific and Industrial Research Organization (CSIRO), which is the national science agency of Australia, is planning to collaborate with local medical technology firms to develop new psychedelic products while also improving the existing products. The agency’s ob...

Cybin (NYSE American: CYBN) (NEO: CYBN) is moving forward with its phase 1/2a clinical trial of its proprietary deuterated psilocybin, CYB003, which, previous research shows, has the potential to effectively treat major depressive disorder (“MDD”) with significant advantages ...